^
Association details:
| Biomarker: | FAT3 mutation |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug Class: | Immunotherapy |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Prognostic and Immunological Role of FAT Family Genes in Non-Small Cell Lung Cancer
Published date:
02/25/2022
Excerpt:
...the relationship between FAT1/2/3/4 mutations and efficacy of immunotherapy was explored in the Hellmann cohort consist of patients with NSCLC...mutant FAT3 was strongly linked to longer PFS relative to wildtype FAT3 (median, NR vs 6.5 months; HR = 0.423; 95% CI: 0.227–0.785; P = .027, Figure 7A) and also tended to have higher BOR rate and DCB rates (Figure 7B and 7C, P > .05).
DOI:
https://doi.org/10.1177/10732748221076682
